Top Back to top

A prospective study on the use of Brentuximab Vedotin or Checkpoint inhibitors as bridge to autologous stem cell transplantation in Hodgkin lymphoma

Lymphoma Working Party (LWP)
Study number:
Short title:
Study status:
Deadline for data collection:
Study design:
Primary objective:
Key inclusion criteria:
Principal investigator:
Ali Bazarbachi
Principal investigator email:
EBMT Study coordinator:
Irma Khvedelidze
Study coordinator email: